search
Back to results

Therapeutic Effects of Berberine in Patients With Type 2 Diabetes

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
Berberine
Metformin
Sponsored by
Shanghai Jiao Tong University School of Medicine
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes focused on measuring Berberine, Type 2 diabetes, Treatment

Eligibility Criteria

25 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Clinical diagnosis of type 2 diabetes
  • HbA1c > 7.0% or FBG > 7.0 mmol/L
  • Stable or worsening glycemic control for at least 3 months

Exclusion Criteria:

  • Liver damage
  • Kidney damage

Sites / Locations

  • Department of Endocrinology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Outcomes

Primary Outcome Measures

HbA1c at 13 weeks

Secondary Outcome Measures

Blood glucose at 13 weeks
Blood lipids at 13 weeks

Full Information

First Posted
January 18, 2007
Last Updated
January 18, 2007
Sponsor
Shanghai Jiao Tong University School of Medicine
Collaborators
National Institutes of Health (NIH)
search

1. Study Identification

Unique Protocol Identification Number
NCT00425009
Brief Title
Therapeutic Effects of Berberine in Patients With Type 2 Diabetes
Official Title
Effects of Berberine on Improvement of Glucose and Lipid Metabolism in Patients With Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
January 2007
Overall Recruitment Status
Completed
Study Start Date
January 2004 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
December 2004 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Shanghai Jiao Tong University School of Medicine
Collaborators
National Institutes of Health (NIH)

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to determine whether berberine is effective in the treatment of type 2 diabetes.
Detailed Description
Type 2 diabetes is health threats worldwide. However, treatment of this disease is limited by availability of effective medicines. All of the existing oral hypoglycemic agents have secondary failure after long term administration. Thus, new oral medicines are needed for long term control of blood glucose in patients with type 2 diabetes. In diabetes care, dietary approaches have drawn more and more attention in the prevention and treatment of hyperglycemia. Generally regarded as safe (GRAS) plants have been widely used for their benefits in antioxidation, anti-inflammation, anticancer, anti-obesity and anti-diabetes. Numerous botanical products such as pigments that include anthocyanins and flavonoids have been consumed or studied for anti-obesity and anti-diabetes. However, most of these botanical products are mixtures of multiple compounds. It is difficult to control their quality in the study or production. Up to now, as a single purified compound, berberine is demonstrated to have hypoglycemic effect in vitro and in vivo. Berberine is the main active component of Coptis chinensis French, which was used for thousands of years in China in the treatment of human diseases including diabetes. Comparison(s): Effects of berberine compared with metformin in newly diagnosed type 2 diabetic patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
Berberine, Type 2 diabetes, Treatment

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
70 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Berberine
Intervention Type
Drug
Intervention Name(s)
Metformin
Primary Outcome Measure Information:
Title
HbA1c at 13 weeks
Secondary Outcome Measure Information:
Title
Blood glucose at 13 weeks
Title
Blood lipids at 13 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Clinical diagnosis of type 2 diabetes HbA1c > 7.0% or FBG > 7.0 mmol/L Stable or worsening glycemic control for at least 3 months Exclusion Criteria: Liver damage Kidney damage
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jun Yin, MD, PhD
Organizational Affiliation
Department of Endocrinology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Endocrinology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine
City
Shanghai
ZIP/Postal Code
200092
Country
China

12. IPD Sharing Statement

Learn more about this trial

Therapeutic Effects of Berberine in Patients With Type 2 Diabetes

We'll reach out to this number within 24 hrs